Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 12/20 | 1.00 |
| ▸ | RPA1 | P27694 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117493 | 0.87 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL116301 | 0.84 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2L3MBTL1PPP1CA | |
| SCHEMBL117471 | 0.78 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2 | |
| SCHEMBL4488017 | 0.78 | RPA1 (1.00) | MARS1RPA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL116342 | 0.77 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2L3MBTL1PPP1CA | |
| SCHEMBL118666 | 0.76 | MARS1 (1.00) | MARS1RPA1SMN1; SMN2L3MBTL1PPP1CA | |
| SCHEMBL1110689 | 0.75 | PPP1CA (0.64) | MARS1RPA1SMN1; SMN2L3MBTL1PPP1CA | |
| SCHEMBL16876821 | 0.75 | MARS1 (0.60) | MARS1RPA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16910537 | 0.75 | MARS1 (0.60) | MARS1RPA1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4493013 | 0.74 | KMT2A (1.00) | MARS1RPA1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885RPA1 1722/4885SMN1; SMN2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.